Transaction will establish partnership between Regenity, Cinven, and legacy investor Linden Capital Partners to support the Company’s next phase of growth. The investment, which is expected to support Regenity’s efforts to scale product development and delivery, comes as the Company looks to expand its manufacturing footprint.

International private equity firm Cinven and Chicago-based Linden Capital Partners (‘Linden’) today announced that Cinven has agreed to make a strategic investment in Regenity Biosciences (‘Regenity’ or ‘the Company’), a global developer and manufacturer of bioresorbable technologies and Linden portfolio company. Financial terms were not disclosed.

Founded in 1997 and headquartered in New Jersey, USA, Regenity has spent nearly 30 years advancing innovative biomaterials that support the body’s natural healing processes for tissue and bone regeneration across multiple clinical areas, including dental, orthopaedic, spine, neurosurgery, advanced wound, sports medicine, ENT, and nerve repair. Today, the Company’s team of over 250 employees serves more than 125 customers with 80+ product lines globally.

Regenity has an established history of product development and manufacturing, demonstrated by a broad portfolio of FDA-approved solutions and over 100 patents, with more than 5 million patients treated in 2025 and over 30 million patients treated since its founding. Its vertically integrated approach combines proprietary materials science, deep technical experience, and a commitment to making a material difference in patient outcomes by taking breakthrough solutions from rapid prototyping to commercial reality.

The investment establishes a partnership between Cinven and Linden, which reflects their shared commitment to supporting high quality healthcare businesses. The firms will partner with Regenity’s management team to further enhance the Company’s longstanding track record of success in developing and commercializing innovative products and next-generation technologies alongside its strategic customers. Cinven is well placed to act as a strategic partner, drawing on its broad pan European presence to support Regenity’s growth across the region.

The combination of Regenity’s operational strength and Cinven’s established track record and global reach positions the Company to accelerate innovation and expand within a large and rapidly growing sector.

Shawn McCarthy, CEO of Regenity Biosciences, commented:
“We believe that Regenity has a tremendous opportunity to continue to drive positive global health outcomes at scale. With the combined support of both Cinven and Linden, Regenity will benefit from an expanded global network, deep industry knowledge, and significant operational resources that will further our continued growth. Our customers trust us to bring meaningful innovation to life, and that responsibility guides everything we do. We’re strengthening our ability to support our customers’ growth, accelerating access to new technologies and ultimately helping more patients benefit from regenerative solutions by combining our deep materials capabilities with global scale and disciplined execution alongside Cinven’s investment.”

Julia Kahr, Partner and Head of the North America Regional team at Cinven, said:
“Regenity has built an impressive position in regenerative biomaterials, underpinned by technical depth, a strong culture, and a clear commitment to improving patient outcomes alongside its customers. We look forward to partnering with Linden and Regenity’s leadership on this next phase of growth.”

Brian Miller, Co-Founder and Partner at Linden Capital Partners, added:
“We are excited to partner with Cinven and to continue supporting Shawn and the Regenity team.”

The transaction is subject to customary regulatory approvals.